| Date | Title | Description |
| 12.03.2026 | Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon | Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon
Thu, Mar 12, 2026 07:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneeri... |
| 27.02.2026 | Cereno Scientific Publishes Year-end Report for 2025 (January 1 – December 31, 2025) | Cereno Scientific Publishes Year-end Report for 2025 (January 1 – December 31, 2025)
Fri, Feb 27, 2026 07:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and ... |
| 02.02.2026 | Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026 | Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026
Mon, Feb 02, 2026 14:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to ... |
| 16.01.2026 | Cereno Scientific: Invitation to Capital Markets Day 2026 | Cereno Scientific: Invitation to Capital Markets Day 2026
Fri, Jan 16, 2026 07:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with... |
| 08.01.2026 | Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP | Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP
Thu, Jan 08, 2026 10:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B) (“the Company”), an innovative... |
| 12.12.2025 | Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026 | Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026
Fri, Dec 12, 2025 07:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatmen... |
| 11.11.2025 | Cereno Scientific Receives SEK 4 million Through Exercise of 600,000 Warrants by Arena Investors, LP | Cereno Scientific Receives SEK 4 million Through Exercise of 600,000 Warrants by Arena Investors, LP
Tue, Nov 11, 2025 07:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B) (“the Company”), an innovative biotech pione... |
| 15.09.2025 | Cereno Scientific Announces Conversion of All Remaining Convertibles Following Request by Fenja Capital II A/S and Arena Investors, LP | Cereno Scientific Announces Conversion of All Remaining Convertibles Following Request by Fenja Capital II A/S and Arena Investors, LP
Mon, Sep 15, 2025 11:15 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B) (“the Comp... |
| 06.08.2025 | Cereno Scientific announces conversion of convertibles following request by Fenja Capital II A/S and Arena Investors, LP | Cereno Scientific announces conversion of convertibles following request by Fenja Capital II A/S and Arena Investors, LP
Wed, Aug 06, 2025 18:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B) (“the Company”), an inno... |
| 20.06.2025 | Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II | Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II
Fri, Jun 20, 2025 08:55 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an inno... |
| 10.06.2025 | Cereno Scientific shares the report from Annual General Meeting 2025 | Cereno Scientific shares the report from Annual General Meeting 2025
Tue, Jun 10, 2025 13:50 CET Report this content
Today, June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå’s premises at Masthamn... |
| 28.05.2025 | Cereno Scientific: Pioneering New Frontiers in Pulmonary Hypertension Treatment | Cereno Scientific is on a mission. A mission to transform the lives of patients suffering from rare cardiovascular and pulmonary diseases. The company, based in Gothenburg, Sweden, is making waves in the biotech industry with its innovative... |
| 27.05.2025 | Cereno Scientific is nominated and shortlisted for ‘Company of the Year’ in the European Mediscience Awards 2025 | Cereno Scientific is nominated and shortlisted for ‘Company of the Year’ in the European Mediscience Awards 2025
Tue, May 27, 2025 08:15 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneerin... |
| 23.05.2025 | Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH) | Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH)
Fri, May 23, 2025 08:20 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an inn... |
| 22.05.2025 | Cereno Scientific publishes Interim Report for Q1 2025 (January 1 – March 31, 2025) | Cereno Scientific publishes Interim Report for Q1 2025 (January 1 – March 31, 2025)
Thu, May 22, 2025 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and e... |
| 15.05.2025 | Cereno Scientific: A Beacon of Hope in Pulmonary Hypertension Treatment | Cereno Scientific is making waves in the biotech world. This innovative company is on a mission to enhance and extend life for those suffering from rare cardiovascular and pulmonary diseases. Their lead candidate, CS1, is a potential game-c... |
| 15.05.2025 | Cereno Scientific publishes Annual Report for 2024 | Cereno Scientific publishes Annual Report for 2024
Thu, May 15, 2025 10:20 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare c... |
| 13.05.2025 | Cereno Scientific presented CS1’s Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025 | Cereno Scientific presented CS1’s Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025
Tue, May 13, 2025 08:31 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneer... |
| 09.05.2025 | Cereno Scientific give notice to attend the Annual General Meeting 2025 | Cereno Scientific give notice to attend the Annual General Meeting 2025
Fri, May 09, 2025 08:30 CET Report this content
The shareholders of Cereno Scientific AB (publ), company registration no. 556890-4071, (the “Company”) are hereby given ... |
| 08.05.2025 | Enzymatica and Cereno Scientific: A Glimpse into the Future of Biotech | In the bustling world of biotechnology, two companies are making waves: Enzymatica AB and Cereno Scientific. Both are charting paths through the complex landscape of health and wellness, each with unique strategies and visions. Their recent... |
| 08.05.2025 | The Pulse of Innovation: Irisity and Cereno Scientific in Focus | In the ever-evolving landscape of technology and healthcare, two companies stand out: Irisity AB and Cereno Scientific. Both are navigating the turbulent waters of their respective industries, armed with innovative solutions and a vision fo... |
| 08.05.2025 | Cereno Scientific's Strategic Shift: A New Board for New Horizons | Cereno Scientific AB is gearing up for a significant transformation. The company is set to propose a new Board of Directors at its Annual General Meeting (AGM) on June 10, 2025. This move signals a shift in strategy, focusing on mergers and... |
| 07.05.2025 | Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025 | Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025
Wed, May 07, 2025 14:00 CET Report this content
The Nomination Committee of Cereno Scientific AB (publ) (th... |
| 07.05.2025 | Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025 | Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025
Wed, May 07, 2025 14:30 CET Report this content
Correction: Thie previous press release stated... |
| 07.05.2025 | Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm | Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm
Wed, May 07, 2025 08:15 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and ... |
| 28.04.2025 | Cereno Scientific to participate at the annual biotech partnering conference LSX Nordics | Cereno Scientific to participate at the annual biotech partnering conference LSX Nordics
Mon, Apr 28, 2025 08:15 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance ... |
| 23.04.2025 | Navigating New Horizons: Checkin.com and Cereno Scientific's Strategic Moves | In the world of business and biotechnology, change is the only constant. Two companies, Checkin.com Group and Cereno Scientific, are making headlines with their recent strategic decisions. Both are charting new paths, driven by innovation a... |
| 22.04.2025 | Cereno Scientific completes successful FDA meeting discussing further clinical development of drug candidate CS1 in rare disease PAH | Cereno Scientific completes successful FDA meeting discussing further clinical development of drug candidate CS1 in rare disease PAH
Tue, Apr 22, 2025 08:15 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovati... |
| 18.04.2025 | Cereno Scientific: Pioneering New Frontiers in Cardiovascular and Pulmonary Treatments | Cereno Scientific is making waves in the biotech ocean. This innovative company is focused on developing treatments for rare cardiovascular and pulmonary diseases. Their flagship drug candidate, CS014, is currently in Phase I trials, and th... |
| 16.04.2025 | Cereno Scientific reports that its Phase I trial of CS014 has been concluded and confirms that top-line results are anticipated in June 2025 | Cereno Scientific reports that its Phase I trial of CS014 has been concluded and confirms that top-line results are anticipated in June 2025
Wed, Apr 16, 2025 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an ... |
| 14.04.2025 | Cereno Scientific to attend BIO International Convention 2025 – largest and most comprehensive event for biotechnology | Cereno Scientific to attend BIO International Convention 2025 – largest and most comprehensive event for biotechnology
Mon, Apr 14, 2025 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pio... |
| 28.02.2025 | Cereno Scientific shares invitation to the webcast for the CS1 Phase IIa trial data presentation at 14:00 CET on March 4 | Cereno Scientific shares invitation to the webcast for the CS1 Phase IIa trial data presentation at 14:00 CET on March 4
Fri, Feb 28, 2025 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech p... |
| 25.02.2025 | Cereno Scientific’s lead candidate CS1’s reverse vascular remodeling profile is accompanied by improvement of right-ventricular function in additional data from Phase IIa trial – webcast on March 4... | Cereno Scientific’s lead candidate CS1’s reverse vascular remodeling profile is accompanied by improvement of right-ventricular function in additional data from Phase IIa trial – webcast on March 4
Tue, Feb 25, 2025 07:30 CET Report this c... |
| 19.02.2025 | Cereno Scientific received approval to initiate sub-study of the CS1 EAP using Fluidda’s innovative imaging technology to obtain insights on the long-term disease-modifying potential of CS1 in PAH | Cereno Scientific received approval to initiate sub-study of the CS1 EAP using Fluidda’s innovative imaging technology to obtain insights on the long-term disease-modifying potential of CS1 in PAH
Wed, Feb 19, 2025 08:52 CET Report this con... |
| 17.02.2025 | Cereno Scientific: Pioneering New Frontiers in Rare Disease Treatment | Cereno Scientific is a beacon of hope in the biotech landscape. This innovative company is dedicated to developing treatments for rare cardiovascular and pulmonary diseases. With a focus on enhancing and extending life, Cereno is making str... |
| 14.02.2025 | Cereno Scientific to attend BIO-Europe Spring 2025 – a leading partnering event for life science in Europe | Cereno Scientific to attend BIO-Europe Spring 2025 – a leading partnering event for life science in Europe
Fri, Feb 14, 2025 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering trea... |
| 11.02.2025 | Cereno Scientific’s HDACi CS014 has successfully completed part one of its Phase I trial evaluating the safety profile with a single ascending dose (SAD) study | Cereno Scientific’s HDACi CS014 has successfully completed part one of its Phase I trial evaluating the safety profile with a single ascending dose (SAD) study
Tue, Feb 11, 2025 08:30 CET Report this content
Cereno Scientific (Nasdaq First ... |
| 06.02.2025 | Cereno Scientific to present at the 2025 Nordic-American Healthcare Conference, the most comprehensive Nordic life science innovation gathering in the US | Cereno Scientific to present at the 2025 Nordic-American Healthcare Conference, the most comprehensive Nordic life science innovation gathering in the US
Thu, Feb 06, 2025 08:00 CET Report this content
Cereno Scientific (Nasdaq First North:... |
| 28.12.2024 | Cereno Scientific Expands Access to Innovative Treatment for Pulmonary Arterial Hypertension | Cereno Scientific is making waves in the biotech ocean. The company has enrolled nine additional patients in its Expanded Access Program (EAP) for CS1, a promising drug candidate aimed at treating pulmonary arterial hypertension (PAH). This... |
| 27.12.2024 | Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH | Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH
Fri, Dec 27, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq Fir... |
| 20.12.2024 | Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated | Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated
Fri, Dec 20, 2024 08:00 CET Report this content
Cereno Scientific (Nas... |
| 19.12.2024 | The Pulse of Innovation: Cereno Scientific and Probi's Strategic Moves in Biotech | In the bustling world of biotechnology, two companies are making headlines: Cereno Scientific and Probi. Both are navigating the complex waters of investment, partnerships, and acquisitions. Their recent activities highlight the dynamic nat... |
| 19.12.2024 | SciBase and Cereno Scientific: Navigating the Waters of Innovation and Investment | In the world of biotechnology and medical technology, companies like SciBase Holding AB and Cereno Scientific are charting their courses through turbulent waters. Both firms are making waves with their recent announcements, showcasing their... |
| 16.12.2024 | New preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at the ASH Annual Meeting and Exposition 2024 | New preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at the ASH Annual Meeting and Exposition 2024
Mon, Dec 16, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovati... |
| 13.12.2024 | Cereno Scientific to present and engage in partnering and investor meetings at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco | Cereno Scientific to present and engage in partnering and investor meetings at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
Fri, Dec 13, 2024 11:40 CET Report this content
Cereno Scientific (Nasdaq First North: ... |
| 06.12.2024 | Cereno Scientific to present preclinical data for drug candidate CS585 at the ASH Annual Meeting and Exposition 2024 | Cereno Scientific to present preclinical data for drug candidate CS585 at the ASH Annual Meeting and Exposition 2024
Fri, Dec 06, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pione... |
| 03.12.2024 | Cereno Scientific reports insider share purchases | Cereno Scientific reports insider share purchases
Tue, Dec 03, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ca... |
| 29.11.2024 | Cereno Scientific reports insider share purchases | Cereno Scientific reports insider share purchases
Fri, Nov 29, 2024 16:15 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ca... |
| 29.11.2024 | Cereno Scientific presents at ABGSC Investor Days, December 5 | Cereno Scientific presents at ABGSC Investor Days, December 5
Fri, Nov 29, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people ... |
| 28.11.2024 | Edison Investment Research publishes an updated research note of Cereno Scientific and an executive CEO interview with Sten R. Sörensen | Edison Investment Research publishes an updated research note of Cereno Scientific and an executive CEO interview with Sten R. Sörensen
Thu, Nov 28, 2024 16:45 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innov... |
| 13.11.2024 | Preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at ESC Congress 2024, now published in European Heart Journal | Preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at ESC Congress 2024, now published in European Heart Journal
Wed, Nov 13, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B),... |
| 11.11.2024 | Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026 | Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026
Mon, Nov 11, 2024 07:25 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech company developing innovative t... |
| 28.10.2024 | Cereno Scientific's Rising Star: A New Hope in Pulmonary Fibrosis Treatment | Cereno Scientific is making waves in the biotech world. The company recently announced a significant increase in its valuation, now pegged at 4.05 billion SEK, or 14.3 SEK per share. This boost comes on the heels of a pivotal decision: the ... |
| 25.10.2024 | Edison Investment Research increases valuation of Cereno Scientific to 4.05 BSEK or SEK 14.3 SEK/share after IPF selected as initial target indication for CS014 | Edison Investment Research increases valuation of Cereno Scientific to 4.05 BSEK or SEK 14.3 SEK/share after IPF selected as initial target indication for CS014
Fri, Oct 25, 2024 10:10 CET Report this content
Cereno Scientific (Nasdaq First... |
| 02.10.2024 | Edison Investment Research increases valuation of Cereno Scientific to 3.9 BSEK or SEK 13.9 SEK/share after positive topline data | Edison Investment Research increases valuation of Cereno Scientific to 3.9 BSEK or SEK 13.9 SEK/share after positive topline data
Wed, Oct 02, 2024 14:54 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering b... |
| 27.09.2024 | Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension | Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension
Fri, Sep 27, 2024 20:40 CET Report this content
Primary endpoint of safety and tolerability met successfully
... |
| 16.08.2024 | Cereno Scientific expands patent protection for PAH drug candidate CS1’s third patent family in Brazil | Cereno Scientific expands patent protection for PAH drug candidate CS1’s third patent family in Brazil
Fri, Aug 16, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovativ... |
| 20.06.2024 | Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I | Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I
Thu, Jun 20, 2024 07:50 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech devel... |
| 10.06.2024 | Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg | Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg
Mon, Jun 10, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments f... |
| 03.06.2024 | Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI) | Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)
Mon, Jun 03, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative t... |
| 30.05.2024 | Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024 | Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024
Thu, May 30, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biote... |
| 28.05.2024 | Cereno Scientific participating at BIO 2024, June 3-6, San Diego | Cereno Scientific participating at BIO 2024, June 3-6, San Diego
Tue, May 28, 2024 08:34 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardi... |
| 23.05.2024 | Cereno Scientific publishes the interim report for Q1 2024 ( January 1–March 31) | Cereno Scientific publishes the interim report for Q1 2024 ( January 1–March 31)
Thu, May 23, 2024 08:30 CET Report this content
The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q1 2024 ( Jan... |
| 17.05.2024 | Cereno Scientific presents at ABGSC Investor Days, May 23 | Cereno Scientific presents at ABGSC Investor Days, May 23
Fri, May 17, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascul... |
| 15.05.2024 | Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress | Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress
Wed, May 15, 2024 09:06 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovativ... |
| 02.05.2024 | Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025 | Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025
Thu, May 02, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for... |
| 16.04.2024 | Report from Annual General Meeting 2024 of Cereno Scientific AB | Report from Annual General Meeting 2024 of Cereno Scientific AB
Tue, Apr 16, 2024 13:05 CET Report this content
Today, April 16, 2024. Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå’s premises at Östra Hamng... |
| 11.04.2024 | Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family | Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family
Thu, Apr 11, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative ... |
| 10.04.2024 | Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014 | Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014
Wed, Apr 10, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a p... |
| 09.04.2024 | Cereno Scientific announces extended patent protection in Europe for CS585 program | Cereno Scientific announces extended patent protection in Europe for CS585 program
Tue, Apr 09, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rar... |
| 03.04.2024 | Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific | Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific
Wed, Apr 03, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innov... |
| 28.03.2024 | Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH | Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH
Thu, Mar 28, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq Fi... |
| 27.03.2024 | Cereno Scientific releases Insights Video Season 3 Episode 8 with Dr. Björn Dahlöf, CSO, Cereno Scientific | Cereno Scientific releases Insights Video Season 3 Episode 8 with Dr. Björn Dahlöf, CSO, Cereno Scientific
Wed, Mar 27, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innov... |
| 26.03.2024 | Cereno Scientific publishes Annual Report for 2023 | Cereno Scientific publishes Annual Report for 2023
Tue, Mar 26, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular dise... |
| 25.03.2024 | Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community | Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community
Mon, Mar 25, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biot... |
| 22.03.2024 | Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1 | Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1
Fri, Mar 22, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatment... |
| 21.03.2024 | Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov | Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov
Thu, Mar 21, 2024 15:08 CET Report this content
Cereno Scientific (Nasdaq First ... |
| 21.03.2024 | Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million | Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million
Thu, Mar 21, 2024 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PA... |
| 19.03.2024 | Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1 | Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1
Tue, Mar 19, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common an... |
| 14.03.2024 | Cereno Scientific's nomination committee proposes Dr. Gunnar Olsson and CEO Sten R. Sörensen as new members of the Board of Directors | Cereno Scientific's nomination committee proposes Dr. Gunnar Olsson and CEO Sten R. Sörensen as new members of the Board of Directors
Thu, Mar 14, 2024 17:19 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company ... |
| 14.03.2024 | Last day of trading with warrants of series TO3 in Cereno Scientific is today, March 14, 2024 | Last day of trading with warrants of series TO3 in Cereno Scientific is today, March 14, 2024
Thu, Mar 14, 2024 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE U... |
| 14.03.2024 | NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OFCERENO Scientific AB (PUBL) | NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OFCERENO Scientific AB (PUBL)
Thu, Mar 14, 2024 15:45 CET Report this content
The shareholders of Cereno Scientific AB (publ), company registration no. 556890-4071 (the “Company”), are hereby give... |
| 14.03.2024 | Cereno Scientific brings forward the publication of the Annual Report | Cereno Scientific brings forward the publication of the Annual Report
Thu, Mar 14, 2024 17:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascu... |
| 14.03.2024 | The Nomination Committee’s proposed resolution to the Annual General Meeting on 16 April 2024 | The Nomination Committee’s proposed resolution to the Annual General Meeting on 16 April 2024
Thu, Mar 14, 2024 17:10 CET Report this content
The Nomination Committee in Cereno Scientific AB (publ) (the “Company”) proposes the following res... |
| 14.03.2024 | Don de Bethizy has been engaged as Senior Advisor to the Executive Management and Board of Directors of Cereno Scientific | Don de Bethizy has been engaged as Senior Advisor to the Executive Management and Board of Directors of Cereno Scientific
Thu, Mar 14, 2024 17:29 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing i... |
| 13.03.2024 | Cereno Scientific to attend BIO-Europe Spring in Barcelona, March 18–20, 2024 | Cereno Scientific to attend BIO-Europe Spring in Barcelona, March 18–20, 2024
Wed, Mar 13, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare car... |
| 12.03.2024 | BioStock has published an interview with Cereno Scientific’s CMO and Head of R&D, Dr. Rahul Agrawal | BioStock has published an interview with Cereno Scientific’s CMO and Head of R&D, Dr. Rahul Agrawal
Tue, Mar 12, 2024 08:52 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatmen... |
| 11.03.2024 | Cereno Scientific releases Insights Videos Season 3 Episode 7 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System | Cereno Scientific releases Insights Videos Season 3 Episode 7 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System
Mon, Mar 11, 2024 08:50 CET Report this content
Cereno Scientific (Nasdaq First North... |
| 06.03.2024 | Cereno Scientific publishes update and study protocol for the FDA approved Expanded Access Program for CS1 in PAH | Cereno Scientific publishes update and study protocol for the FDA approved Expanded Access Program for CS1 in PAH
Wed, Mar 06, 2024 08:30 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovativ... |
| 05.03.2024 | The exercise period for warrants of series TO3 in Cereno Scientific begins today | The exercise period for warrants of series TO3 in Cereno Scientific begins today
Tue, Mar 05, 2024 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES,... |
| 04.03.2024 | The exercise price for the warrants of series TO3 in Cereno Scientific has been determined to SEK 1.60 per share of series B | The exercise price for the warrants of series TO3 in Cereno Scientific has been determined to SEK 1.60 per share of series B
Mon, Mar 04, 2024 08:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, D... |
| 29.02.2024 | Cereno Scientific reports one new patient enrolled, one additional patient randomized, and one additional patient completed in the Phase II Study of CS1 in PAH | Cereno Scientific reports one new patient enrolled, one additional patient randomized, and one additional patient completed in the Phase II Study of CS1 in PAH
Thu, Feb 29, 2024 08:48 CET Report this content
Cereno Scientific (Nasdaq First ... |
| 28.02.2024 | Cereno Scientific to present at Life Science-dagen in Gothenburg on March 6, 2024 | Cereno Scientific to present at Life Science-dagen in Gothenburg on March 6, 2024
Wed, Feb 28, 2024 08:35 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare... |
| 27.02.2024 | Cereno Scientific releases Insights Videos Season 3 Episode 6 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System | Cereno Scientific releases Insights Videos Season 3 Episode 6 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System
Tue, Feb 27, 2024 08:17 CET Report this content
Cereno Scientific (Nasdaq First North... |
| 26.02.2024 | Edison Investment Research publishes Executive Interview with Rahul Agrawal, CMO and Head of R&D; and Björn Dahlöf, CSO, Cereno Scientific | Edison Investment Research publishes Executive Interview with Rahul Agrawal, CMO and Head of R&D; and Björn Dahlöf, CSO, Cereno Scientific
Mon, Feb 26, 2024 09:44 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a... |
| 23.02.2024 | Cereno Scientific releases Insights Videos Season 3 Episode 5 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System | Cereno Scientific releases Insights Videos Season 3 Episode 5 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System
Fri, Feb 23, 2024 08:51 CET Report this content
Cereno Scientific (Nasdaq First North... |
| 22.02.2024 | Cereno Scientific publishes year-end report for 2023 (1 January – 31 December) | Cereno Scientific publishes year-end report for 2023 (1 January – 31 December)
Thu, Feb 22, 2024 00:01 CET Report this content
The Board and Chief Executive Officer of Cereno Scientific AB here presents the year-end report for the year 2023... |
| 22.02.2024 | Edison Investment Research publishes first research on Cereno Scientific | Edison Investment Research publishes first research on Cereno Scientific
Thu, Feb 22, 2024 06:52 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiova... |
| 22.02.2024 | Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific | Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific
Thu, Feb 22, 2024 17:04 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatment... |
| 22.02.2024 | Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding recent announcements and the Year-End-report (Q4) | Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding recent announcements and the Year-End-report (Q4)
Thu, Feb 22, 2024 14:48 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), a company de... |
